Recruiting

Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients

Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important…

ClinicalTrials.gov IDNCT06427018
PhaseNot Applicable
Enrollment120
SponsorLei-Miao Yin
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Asthma, Protein

About this study

Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Lung tissue samples; * The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment; * Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle; * Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle. Exclusion Criteria: * Paraffin sections of lung tissue from patients who have been diagnosed with COPD; * Other situations where the researcher deems it inappropriate to participate in this study.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.